IRIS
ROSSI, Marco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 119
NA - Nord America 8
AS - Asia 1
Totale 128
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 114
US - Stati Uniti d'America 8
NL - Olanda 3
CZ - Repubblica Ceca 1
DE - Germania 1
IN - India 1
Totale 128
Salva come PNG Salva come JPEG
Città #
Catanzaro 11
Naples 6
Palermo 6
Settingiano 4
Ashburn 3
Naaldwijk 3
Fleming Island 2
Ahmedabad 1
Cerchiara di Calabria 1
Council Bluffs 1
Düsseldorf 1
Lamezia Terme 1
Milan 1
Pellaro 1
Rende 1
Totale 43
Salva come PNG Salva come JPEG
Nome #
CD7+ acute leukemia switching from a lymphoid to a myeloid phenotype, file de164cb3-d7d9-6b31-e053-1705fe0a395c 9
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling, file de164cb4-3389-6b31-e053-1705fe0a395c 8
Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety, file de164cb4-2d52-6b31-e053-1705fe0a395c 7
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells, file c90dd740-b4a3-44fe-9058-970b00ed611e 6
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia, file bd2fc93e-50af-4405-b3db-9d6b41d3786a 5
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma., file de164cb3-e7b3-6b31-e053-1705fe0a395c 5
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report, file de164cb4-73a9-6b31-e053-1705fe0a395c 5
Therapeutic activation of G protein-coupled estrogen receptor 1 in Waldenström Macroglobulinemia, file 3f6387b2-7039-4c07-877c-7ec592547550 4
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling, file de164cb3-ca3a-6b31-e053-1705fe0a395c 4
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma, file de164cb4-34eb-6b31-e053-1705fe0a395c 4
Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation), file de164cb3-bef7-6b31-e053-1705fe0a395c 3
Multiple myeloma-related bone disease: state-of-art and future treatments, file de164cb3-caad-6b31-e053-1705fe0a395c 3
Synthetic miR-34a Mimics as a Novel Therapeutic Agent for Multiple Myeloma: In Vitro and In Vivo Evidence, file de164cb3-d8d8-6b31-e053-1705fe0a395c 3
miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1, file de164cb3-e216-6b31-e053-1705fe0a395c 3
Challenging the Current Approaches to Multiple Myeloma-Related Bone Disease: From Bisphosphonates to Target Therapy, file de164cb3-e7e7-6b31-e053-1705fe0a395c 3
In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor, file de164cb3-e7e8-6b31-e053-1705fe0a395c 3
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomised trials, file de164cb3-e7ec-6b31-e053-1705fe0a395c 3
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival, file de164cb3-e7ed-6b31-e053-1705fe0a395c 3
A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells, file de164cb3-e7f2-6b31-e053-1705fe0a395c 3
Depression of lymphocyte activity during cutaneous leishmaniasis: a case report., file de164cb3-ea68-6b31-e053-1705fe0a395c 3
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma, file de164cb3-f754-6b31-e053-1705fe0a395c 3
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant, file de164cb4-1650-6b31-e053-1705fe0a395c 3
Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials, file de164cb4-1ad8-6b31-e053-1705fe0a395c 3
Acute lymphoblastic leukemia in the context of a disorder resembling X-linked lymphoproliferative (XLP) syndrome, file de164cb3-bef6-6b31-e053-1705fe0a395c 2
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma., file de164cb3-c735-6b31-e053-1705fe0a395c 2
Dendritic cells have the option to express IDO-mediated suppression or not, file de164cb3-d41d-6b31-e053-1705fe0a395c 2
Whole-body MRI and PET/CT in multiple myeloma patients during staging and after treatment: personal experience in a longitudinal study., file de164cb3-d68a-6b31-e053-1705fe0a395c 2
Targeting miR-21 Inhibits In Vitro and In Vivo Multiple Myeloma Cell Growth, file de164cb3-db14-6b31-e053-1705fe0a395c 2
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma, file de164cb3-e7e9-6b31-e053-1705fe0a395c 2
Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts, file de164cb3-e7f4-6b31-e053-1705fe0a395c 2
The non-coding RNA landscape of plasma cell dyscrasias, file de164cb4-164d-6b31-e053-1705fe0a395c 2
New Approaches to Predict Outcome and Personalize Therapy in Multiple Myeloma: from microRNAs to Integrated Genomics, file de164cb3-d72a-6b31-e053-1705fe0a395c 1
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells, file de164cb3-d982-6b31-e053-1705fe0a395c 1
Genetics and molecular profiling of multiple myeloma: Novel tools for clinical management?, file de164cb3-df6b-6b31-e053-1705fe0a395c 1
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells, file de164cb3-e380-6b31-e053-1705fe0a395c 1
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92, file de164cb3-e386-6b31-e053-1705fe0a395c 1
Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma, file de164cb3-e7ea-6b31-e053-1705fe0a395c 1
MicroRNA and Multiple Myeloma: from Laboratory Findings to Translational Therapeutic Approaches, file de164cb3-e7eb-6b31-e053-1705fe0a395c 1
MicroRNAs in multiple myeloma and related bone disease, file de164cb3-e7ef-6b31-e053-1705fe0a395c 1
From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario, file de164cb3-e7f0-6b31-e053-1705fe0a395c 1
miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells, file de164cb3-e7f1-6b31-e053-1705fe0a395c 1
null, file de164cb3-e7f7-6b31-e053-1705fe0a395c 1
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity., file de164cb3-eab8-6b31-e053-1705fe0a395c 1
A Comprehensive Safety Evaluation of Trabectedin and Drug-Drug Interactions of Trabectedin-Based Combinations, file de164cb3-ed5c-6b31-e053-1705fe0a395c 1
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo, file de164cb3-f48e-6b31-e053-1705fe0a395c 1
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma, file de164cb4-355e-6b31-e053-1705fe0a395c 1
null, file de164cb4-50c7-6b31-e053-1705fe0a395c 1
Totale 128
Salva come PNG Salva come JPEG
Categoria #
all - tutte 171
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 171
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204 0 0 0 2 1 0 0 1 0 0 0 0
2020/202182 0 0 1 0 0 0 0 80 1 0 0 0
2021/20222 0 0 0 0 0 0 0 0 0 0 2 0
2022/202338 0 0 3 4 0 3 4 5 1 2 15 1
2023/20242 0 2 0 0 0 0 0 0 0 0 0 0
Totale 128